Continued Influence of PTAB Proceedings on Bio/Pharma Patents (Live MBHB Webinar)

Tues., Sept. 18, 2018 | 10:00-11:15 a.m. CT | Live MBHB Webinar via WebEx 

Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB) have become established mechanisms to challenge bio/pharma patents.  But these proceedings are still very young and continually evolving.  Many recent changes, including the Supreme Court’s SAS decision and the PTAB’s proposed rulemaking regarding claim construction, and even Senator Hatch’s suggested legislative changes are having /will have a significant impact on the strategies used by both petitioners and patent owners in these PTAB proceedings – particularly in the bio/pharma space. Join us as we discuss the following topics:

  • A review of how bio/pharma patents have fared before the PTAB;
  • An analysis of how PTAB proceedings are impacting ANDA and biosimilar litigations;
  • A discussion of how the Supreme Court’s recent SAS decision is impacting PTAB invalidity proceedings in the bio/pharma space;
  • A discussion of how the PTAB’s proposed rulemaking regarding the claim construction standard could impact bio/pharma patents; and
  • A discussion regarding potential legislative action to alter the impact of PTAB proceedings on ANDA litigation.


Presenter(s): MBHB attorney Alison Baldwin and Paula Fritsch, Ph.D.

McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.

NOTE: MCLE credit is not available for this archived recording. 

Access an archived audio version of this webinar here